. | Biochemical recurrenceb . | Lethal prostate cancerb . | Prostate cancer death . | Non–prostate cancer death . | ||||
---|---|---|---|---|---|---|---|---|
. | More variable length among cancer cells . | Shorter length in associated stromal cells . | More variable length among cancer cells . | Shorter length in associated stromal cells . | More variable length among cancer cells . | Shorter length in associated stromal cells . | More variable length among cancer cells . | Shorter length in associated stromal cells . |
Age and year of diagnosis adjusted | ||||||||
HR (95% CI) | 1.88 (1.39–2.55) | 0.92 (0.67–1.26) | 2.56 (1.50–4.37) | 1.95 (1.01–3.78) | 3.07 (1.71–5.51) | 2.37 (1.11–5.08) | 1.29 (0.91–1.82) | 0.73 (0.52–1.02) |
Multivariable adjustedc | ||||||||
HR (95% CI) | 1.51 (1.11–2.07) | 0.96 (0.70–1.31) | 1.64 (0.94–2.86) | 2.43 (1.24–4.76) | 1.78 (0.96–3.30) | 2.94 (1.35–6.39) | 1.25 (0.88–1.78) | 0.73 (0.52–1.02) |
Additionally mutually adjustedd | ||||||||
HR (95% CI) | 1.55 (1.12–2.15) | 1.10 (0.79–1.54) | 2.21 (1.24–3.95) | 3.39 (1.65–6.98) | 2.39 (1.26–4.51) | 4.18 (1.8–9.67) | 1.17 (0.81–1.68) | 0.76 (0.54–1.08) |
. | Biochemical recurrenceb . | Lethal prostate cancerb . | Prostate cancer death . | Non–prostate cancer death . | ||||
---|---|---|---|---|---|---|---|---|
. | More variable length among cancer cells . | Shorter length in associated stromal cells . | More variable length among cancer cells . | Shorter length in associated stromal cells . | More variable length among cancer cells . | Shorter length in associated stromal cells . | More variable length among cancer cells . | Shorter length in associated stromal cells . |
Age and year of diagnosis adjusted | ||||||||
HR (95% CI) | 1.88 (1.39–2.55) | 0.92 (0.67–1.26) | 2.56 (1.50–4.37) | 1.95 (1.01–3.78) | 3.07 (1.71–5.51) | 2.37 (1.11–5.08) | 1.29 (0.91–1.82) | 0.73 (0.52–1.02) |
Multivariable adjustedc | ||||||||
HR (95% CI) | 1.51 (1.11–2.07) | 0.96 (0.70–1.31) | 1.64 (0.94–2.86) | 2.43 (1.24–4.76) | 1.78 (0.96–3.30) | 2.94 (1.35–6.39) | 1.25 (0.88–1.78) | 0.73 (0.52–1.02) |
Additionally mutually adjustedd | ||||||||
HR (95% CI) | 1.55 (1.12–2.15) | 1.10 (0.79–1.54) | 2.21 (1.24–3.95) | 3.39 (1.65–6.98) | 2.39 (1.26–4.51) | 4.18 (1.8–9.67) | 1.17 (0.81–1.68) | 0.76 (0.54–1.08) |
aAssociations are reported as HR and 95% CI for the following comparisons: more variable (top tertile of variability) in telomere length among prostate cancer cells versus less variable (bottom and middle tertiles), and shorter (shortest and middle tertiles) median telomere length in CAS cells versus longer (longest tertile).
bRestricted to men without metastatic prostate cancer at the time of diagnosis.
cAdjusted for age (continuous) and year (continuous) of diagnosis, prostatectomy Gleason sum (categorical: ≤6, 3 + 4, 4 + 3, ≥8), pathologic TNM stage (categorical ≥T3b), and serum PSA concentration at diagnosis (categorical: <10, 10–20, >20 ng/mL, unknown).
dAssociation with more variable telomere length among prostate cancer cells further adjusted for shorter telomere length in prostate CAS cells; association with shorter telomere length in prostate CAS cells further adjusted for more variable telomere length among prostate cancer cells.